The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.
Data last updated: Oct 19, 2026
Snapshot (as of Oct 19, 2026): GSK plc (GSK) pays a $0.68 annual dividend ($0.17 quarterly), yielding 3.67% at $49.51/share. Next ex-dividend date 2026-08-14. Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 3.67%
Annual Dividend: $0.68 per share
Payout Ratio: 56.5%
Ex-Dividend Date: 2026-08-14
Dividend Frequency: quarterly
Sector: Healthcare
Years of Dividend History: 43
GSK plc is a global pharmaceutical company with over three centuries of history, producing vaccines, HIV therapies, and treatments for respiratory conditions like asthma and COPD. The GSK plc dividend currently yields 3.83%, paid quarterly, with a trailing annual rate of $1.36 per share and the next ex-dividend date set for August 14, 2026. With a beta of 0.29, GSK stock moves far less than the broader market, which suits income-focused investors who prioritize low volatility over price appreciation.
GSK plc pays out 55.3% of earnings as dividends, a payout ratio classified as moderate (40-60%). That level leaves a meaningful buffer from earnings, supported by a business built around recurring demand for vaccines against shingles, meningitis, and RSV, alongside specialty medicines for HIV and oncology. GSK plc dividend safety faces its main pressure from the pharmaceutical sector's exposure to patent cliffs and pipeline risk, neither of which is reflected in the payout ratio itself but both of which can affect the earnings base that supports it.
GSK plc dividend history shows a CAGR of -1.3% per year from 2008 to 2025. Per-share payments moved from $2.14 at the start of the window to $1.70 by 2025 (with 2026 partial and excluded from the CAGR calculation). The largest annual increase in the window was 13.1% in 2016, but the overall trend has been negative, and the history table contains at least one year-over-year decline exceeding 5%. For income investors focused on dividend growth, that trajectory is a clear drawback.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | +0.3% | $1.68 (2022) | $1.70 (2025) |
| 5-Year | -3.8% | $2.06 (2020) | $1.70 (2025) |
| 10-Year | -3.6% | $2.45 (2015) | $1.70 (2025) |
GSK plc fits income-focused investors who want pharmaceutical sector exposure with low market sensitivity, not those chasing dividend growth. The current yield of 3.83% sits in the moderate (2-4%) range and runs slightly above the 5-year average of 3.68%, which means the stock is not offering a historically unusual premium. The payout ratio of 55.3% supports the current payment level, but the long-run CAGR of -1.3% per year means purchasing power from the dividend has eroded over time. What an investor gets here is a low-beta healthcare name with a mid-range yield. What they give up is any meaningful dividend growth.
| Payment Date | Amount per Share |
|---|---|
| 2026-08-14 | $0.4515 |
| 2026-05-15 | $0.4550 |
| 2026-02-20 | $0.4776 |
| 2025-11-14 | $0.4331 |
| 2025-08-15 | $0.4300 |
| 2025-05-16 | $0.4348 |
| 2025-02-21 | $0.4007 |
| 2024-11-15 | $0.3891 |
| 2024-08-16 | $0.3857 |
| 2024-05-16 | $0.3762 |
| Year | Total Dividends |
|---|---|
| 2026 | $1.3841 |
| 2025 | $1.6986 |
| 2024 | $1.5570 |
| 2023 | $1.3905 |
| 2022 | $1.6811 |
Project income from GSK with the GSK dividend calculator or track your full portfolio with the dividend tracker.